人類肝臟模型市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品（2D 模型、3D 生物列印、肝臟類器官）、按應用（藥物發現、學術與研究）、按地區細分，按比賽

2022 年全球人類肝臟模型市場價值為 5.6745 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年CAGR為4.17%。全球人類肝臟模型市場是指創新和先進系統、技術的市場，以及旨在模擬人類肝臟的結構和功能的模型，用於各種應用，特別是在藥物開發和毒理學測試中。這些肝臟模型是藥物研究中的寶貴工具，使研究人員和組織能夠研究肝臟相關疾病、測試新藥的安全性和有效性，並減少動物試驗的需要。

主要市場促進因素

藥物研究進展

市場概況
預測期	2024-2028
2022 年市場規模	5.6745億美元
2028 年市場規模	7.2561億美元
2023-2028 年CAGR	4.17%
成長最快的細分市場	肝臟類器官
最大的市場	北美洲

全球人類肝臟模型市場正在經歷需求的變革性激增，這在很大程度上是由藥物研究的快速進步所推動的。隨著製藥業面臨越來越大的壓力，需要開發更安全、更有效的藥物，同時減少時間和成本，人類肝臟模型已成為不可或缺的工具。

道德問題和監管壓力

全球人類肝臟模型市場正在經歷重大變革，這不僅受到科學進步的推動，而且受到深刻的倫理問題和監管壓力的推動。在倫理考量與科學進步日益交織在一起的時代，人類肝臟模型已成為符合不斷發展的法規的倫理替代品。

倫理考量已成為科學研究實踐的核心。對動物福利和動物測試的道德影響的擔憂導致了對研究方法的重新評估。人類肝臟模型提供了一種人道且符合倫理的解決方案，使研究人員無需對動物進行實驗即可獲得與人類相關的資料。

嚴重依賴臨床前測試的製藥業越來越認知到倫理研究實踐的重要性。製藥公司面臨證明其對道德研究和永續發展承諾的壓力，而採用人體肝臟模型被視為一種負責任的選擇。這種一致性正在推動藥物開發中對肝臟模型的需求。

美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等世界各地的監管機構已開始強調倫理研究實踐的重要性。這些機構鼓勵使用動物試驗的替代方案，其中包括人類肝臟模型，以收集與人類反應更相關的資料。

倫理問題延伸到研究中動物試驗的減少。人類肝臟模型是這種減少策略的關鍵部分。它們提供了一種進行臨床前測試的方法，而不會出現與動物實驗相關的道德兩難。監管機構正在積極推動這一轉變，推動製藥公司探索替代方法。

監管要求不斷變化，以適應在臨床前測試中使用人體肝臟模型。例如，FDA 已發布指南，強調在藥物開發過程早期獲取人類特異性資料的重要性。滿足這些不斷變化的監管要求需要先進的人類肝臟模型。

倫理問題不僅限於科學界，也延伸到公眾。消費者越來越意識到他們使用的產品（包括藥物）的道德影響。這種意識要求製藥公司優先考慮道德研究實踐，並考慮動物試驗的替代方案。

肝病發生率上升

在令人擔憂的全球趨勢（肝病發病率不斷上升）的推動下，全球人類肝臟模型市場的需求正在激增。隨著肝臟相關疾病繼續在全球範圍內構成重大健康挑戰，人類肝臟模型正在成為研究、藥物開發和個人化醫療不可或缺的工具。

肝臟疾病，包括肝炎、肝硬化、非酒精性脂肪肝（NAFLD）和肝癌，已成為日益嚴重的公共衛生問題。不健康的生活方式、酗酒、病毒感染和肥胖等因素導致全球肝病發生率上升。

隨著肝病盛行率的增加，迫切需要更有效的療法和治療方法。傳統的藥物開發過程經常面臨預測藥物如何影響人類肝臟的挑戰。人類肝臟模型提供了一個逼真的環境來研究疾病進展和測試潛在的治療方法，這使得它們在尋求更好的治療方法中具有無價的價值。

個人化醫療時代正在徹底改變醫療保健。人類肝臟模型使研究人員能夠研究個別患者對特定藥物的反應。透過在這些模型中使用患者來源的肝組織，可以根據患者獨特的基因組成和疾病特徵來客製化治療方法。

肝病在全球造成了巨大的經濟和醫療負擔。透過增進我們對這些疾病的了解並開發更有效的治療方法，人類肝臟模型可以有助於降低與肝臟相關疾病相關的社會和經濟成本。

人類肝臟模型對於研究肝臟疾病的機制具有不可估量的價值。它們提供了一個在細胞層面上研究疾病進展並識別肝病早期生物標記的平台，從而有可能實現早期診斷和干涉。

藥物發現和開發是資源密集過程。人體肝臟模型使製藥公司能夠更有效地篩選潛在的治療方法，降低後期藥物失敗的可能性。藥物開發流程的簡化正在推動製藥業對肝臟模型的需求。

技術進步

全球人類肝臟模型市場目前正在經歷一場顯著的轉變，這在很大程度上是由快速技術進步所推動的。這些創新正在徹底改變肝臟研究、藥物開發和個人化醫療領域。

3D 生物列印和組織工程的技術進步改變了人類肝臟模型的面貌。研究人員現在可以創造出高度複雜且生理上精確的肝臟組織，與真實的器官非常相似。這項創新顯著增強了人類肝臟模型在藥物測試和疾病研究中的相關性和可靠性。

器官晶片技術已經成為肝臟建模領域的遊戲規則改變者。這些微流體裝置複製了肝臟的生理狀況，從而能夠即時監測和分析肝功能。器官晶片系統的精確度和可擴展性為肝臟研究和藥物測試開闢了新途徑。

微加工技術使得微型肝臟模型的開發成為可能，並且能夠精確控制細胞的佈局和結構。這些模型可以對候選藥物進行高通量篩選，並為肝病機制提供有價值的見解。

技術的進步使得創建模仿肝臟和體內其他器官之間相互作用的多器官系統成為可能。這些系統可以更全面地了解藥物和疾病如何影響整個人體，從而促進更準確地評估候選藥物的安全性和有效性。

高解析度顯微鏡和先進分析工具等尖端成像技術使研究人員能夠密切監測和分析肝臟模型的行為。對細胞和分子過程的詳細了解增強了我們對肝功能和疾病進展的理解。

人工智慧和機器學習演算法正在整合到肝臟建模中，以分析先進技術產生的大量資料集。這些人工智慧驅動的方法有助於預測藥物反應、識別潛在的生物標記並最佳化實驗條件，最終加速研究和開發。

技術進步有助於提高人類肝臟模型的可重複性和可擴展性。這使得研究人員和製藥公司更容易進行大規模實驗並提高藥物篩選過程的效率。

主要市場挑戰

肝功能的複雜性

肝臟是一個極其複雜的器官，具有多種功能，包括解毒、新陳代謝和蛋白質合成。在模型中準確複製其所有功能具有挑戰性。研究人員正在努力提高肝臟模型的生理相關性，但要實現完整的模擬仍然是一項艱鉅的任務。

長期生存能力

長期維持人類肝臟模型的活力和功能是一項挑戰。這些模型中的細胞會隨著時間的推移而惡化，影響實驗結果的可靠性。研究人員正在探索生物列印和器官晶片技術等策略來解決這個問題。

與其他器官的相互作用

雖然單一肝臟模型提供了有價值的見解，但了解肝臟如何與其他器官相互作用對於綜合研究至關重要。開發能夠準確複製這些相互作用的多器官系統是研究人員正在積極應對的挑戰。

主要市場趨勢

多重器官晶片系統

多重器官晶片系統的發展是一個突破性的趨勢。這些平台能夠研究肝臟和其他器官之間的相互作用，從而更全面地了解藥物和疾病如何影響整個人體。這些模型為推動藥物開發和個人化醫療帶來了巨大的希望。

先進的組織工程和 3D 生物列印

組織工程和 3D 生物列印技術正在迅速發展。這些創新允許創造高度複雜且生理精確的肝臟組織，非常模仿真實的器官。肝臟模型日益複雜，增強了其在藥物測試中的相關性和可靠性。

微流體和晶片實驗室設備

微流體和晶片實驗室設備變得越來越複雜，能夠精確控制實驗條件。這些平台提供肝功能的即時監測和分析，為藥物反應和疾病機制提供有價值的見解。

細分市場洞察

產品洞察

根據產品類別，出於幾個令人信服的原因，2D 模型有望保持在全球人類肝臟模型市場的主導地位。首先，它們為研究肝臟相關疾病和藥物測試提供了經濟有效的解決方案，使其成為研究機構和製藥公司的有吸引力的選擇。此外，多年來，二維模型已被廣泛採用和驗證，為持續使用奠定了堅實的基礎。它們的簡單性和易用性也有助於它們的持久流行。此外，隨著細胞培養技術和檢測開發的進步不斷增強 2D 模型的相關性和準確性，它們可能仍然是肝臟研究的首選。未來幾年，肝臟相關研究不斷成長的需求以及二維模型的實際優勢預計將鞏固其在市場上的主導地位。

應用洞察

根據應用，出於幾個令人信服的原因，藥物發現將繼續主導全球人類肝臟模型市場。首先也是最重要的是，製藥業對創新和有效療法的持續追求推動了對可靠的肝臟模型來評估候選藥物的持續需求。人體肝臟模型在早期藥物測試中發揮著不可替代的作用，使研究人員能夠準確評估藥物代謝、毒性和療效。此外，藥物標靶的日益複雜性和個人化醫療的推動需要更複雜的肝臟模型，這將藥物發現定位為該市場創新的關鍵驅動力。隨著組織工程和生物技術的不斷進步，藥物發現可能在未來幾年保持其主導地位，確保全球人類肝臟模型市場繼續蓬勃發展。

區域洞察

預計到 2022 年，北美和歐洲將佔據最大的市場佔有率，這主要歸功於這些地區在研發方面不斷增加的投資、器官模型的進步以及對創新治療可能性的接受。此外，肝病發生率的上升，加上主要市場參與者的存在，預計將在預測期內推動市場擴張。此外，由於亞太地區新興國家的研發投資不斷增加，該地區的市場佔有率也將增加。此外，醫療保健基礎設施的持續發展以及公司對創新療法的高度關注都將促進該地區的成長。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按地區
  • 按公司分類 (2022)
• 產品市場地圖
  • 按產品分類
  • 按應用
  • 按地區

第 6 章：北美人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太地區人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國

第 9 章：南美洲人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲人類肝臟模型市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（2D 模型、3D 生物列印、肝臟類器官）
  • 按應用（藥物發現、學術與研究）
  • 按國家/地區
• MEA：國家分析
  • 南非人體肝臟模型
  • 沙烏地阿拉伯人體肝臟模型
  • 阿拉伯聯合大公國人類肝臟模型
  • 科威特人類肝臟模型

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• 商業概覽
• 產品供應
• 最近的發展
• 財務（據報導）
• 主要人員
• SWOT分析
  • Organovo Holdings Inc
  • BioIVT LLC
  • InSphero AG
  • Emulate Inc
  • Mimetas BV
  • CN Bio
  • Cyfuse Biomedical KK
  • Hurel Corp

第 15 章：策略建議

第 16 章：關於我們與免責聲明

Global Human Liver Model Market has valued at USD 567.45 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.17% through 2028. The Global Human Liver Model Market refers to the market for innovative and advanced systems, technologies, and models designed to mimic the structure and functions of the human liver for various applications, particularly in drug development and toxicology testing. These liver models serve as valuable tools in pharmaceutical research, enabling researchers and organizations to study liver-related diseases, test the safety and efficacy of new drugs, and reduce the need for animal testing.

Key Market Drivers

Pharmaceutical Research Advancements

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 567.45 Million
Market Size 2028	USD 725.61 Million
CAGR 2023-2028	4.17%
Fastest Growing Segment	Liver Organoids
Largest Market	North America

The Global Human Liver Model Market is experiencing a transformative surge in demand, driven in large part by the rapid advancements in pharmaceutical research. As the pharmaceutical industry faces increasing pressure to develop safer and more effective drugs while reducing time and costs, human liver models have emerged as indispensable tools.

Pharmaceutical companies are continually searching for more efficient and accurate ways to evaluate drug candidates. Human liver models provide a realistic and dynamic environment to test potential drugs, predict their pharmacokinetics, and assess their toxicity. This level of precision significantly reduces the risk of late-stage clinical trial failures, leading to substantial cost savings and a more streamlined drug development process.

The pharmaceutical landscape is shifting towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and unique disease profiles. Human liver models play a pivotal role in this paradigm by allowing researchers to test drug responses on patient-derived liver tissue. Advancements in this area are driving demand for more advanced liver models, leading to innovations and market growth.

Regulatory bodies like the FDA are increasingly emphasizing the need for human-relevant data in drug development and safety assessments. Human liver models, with their ability to mimic human liver functions accurately, are becoming a preferred choice for preclinical studies. As regulatory guidelines evolve to reflect this trend, pharmaceutical companies are investing in these models to ensure compliance and streamline the drug approval process.

Recent global health crises, such as the COVID-19 pandemic, have underscored the urgency of rapid drug development. Human liver models have played a crucial role in studying the impact of viruses on the liver and screening potential treatments. These models enable scientists to expedite research during health emergencies, increasing their importance in the pharmaceutical research landscape.

Ethical concerns and a desire for more humane research practices have led to a push for reduced animal testing. Human liver models provide a viable alternative that allows researchers to obtain human-specific data without harming animals. Pharmaceutical companies are increasingly adopting these models as part of their commitment to ethical research and to meet changing regulatory requirements.

Collaboration between pharmaceutical companies, academic institutions, and technology firms is driving innovation in human liver models. Partnerships leverage collective expertise and resources to develop more advanced and scalable models. These collaborative efforts have the potential to accelerate the growth of the human liver model market.

Ethical Concerns and Regulatory Pressures

The Global Human Liver Model Market is undergoing a significant transformation, driven not only by scientific advancements but also by profound ethical concerns and regulatory pressures. In an era where ethical considerations are increasingly intertwined with scientific progress, human liver models have emerged as ethical alternatives that align with evolving regulations.

Ethical considerations have become central to the practice of scientific research. Concerns about the welfare of animals and the moral implications of animal testing have led to a reevaluation of research methodologies. Human liver models offer a humane and ethical solution, allowing researchers to obtain human-relevant data without subjecting animals to experimentation.

The pharmaceutical industry, which relies heavily on preclinical testing, is increasingly recognizing the importance of ethical research practices. Pharmaceutical companies are under pressure to demonstrate their commitment to ethical research and sustainability, and the adoption of human liver models is viewed as a responsible choice. This alignment is driving demand for liver models in drug development.

Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have started to emphasize the importance of ethical research practices. These agencies are encouraging the use of alternatives to animal testing, which includes human liver models, to gather data that is more relevant to human responses.

Ethical concerns extend to the reduction of animal testing in research. Human liver models are a key part of this reduction strategy. They provide a way to conduct preclinical testing without the ethical dilemmas associated with animal experiments. Regulatory bodies are actively promoting this transition, pushing pharmaceutical companies to explore alternative methods.

Regulatory requirements are evolving to accommodate the use of human liver models in preclinical testing. For instance, the FDA has issued guidelines that emphasize the importance of obtaining human-specific data early in the drug development process. Meeting these changing regulatory requirements necessitates the adoption of advanced human liver models.

Ethical concerns are not limited to the scientific community but extend to the general public. Consumers are increasingly conscious of the ethical implications of the products they use, including medications. This awareness has created a demand for pharmaceutical companies to prioritize ethical research practices and consider alternatives to animal testing.

Rising Incidence of Liver Diseases

The Global Human Liver Model Market is witnessing an upsurge in demand, driven by a concerning global trend - the increasing incidence of liver diseases. As liver-related disorders continue to pose significant health challenges worldwide, human liver models are emerging as indispensable tools for research, drug development, and personalized medicine.

Liver diseases, including hepatitis, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and liver cancer, have become a growing public health concern. Factors such as unhealthy lifestyles, alcohol abuse, viral infections, and obesity contribute to the rising incidence of liver diseases globally.

As the prevalence of liver diseases increases, there is an urgent need for more effective therapies and treatments. Traditional drug development processes often face challenges in predicting how drugs will affect the human liver. Human liver models offer a lifelike environment to study disease progression and test potential treatments, making them invaluable in the quest for better therapies.

The era of personalized medicine is revolutionizing healthcare. Human liver models enable researchers to study how individual patients may respond to specific drugs. By using patient-derived liver tissue in these models, treatments can be tailored to the patient's unique genetic makeup and disease characteristics.

Liver diseases impose a significant economic and healthcare burden globally. By advancing our understanding of these diseases and developing more effective treatments, human liver models can contribute to reducing the societal and economic costs associated with liver-related disorders.

Human liver models are invaluable for researching the mechanisms of liver diseases. They provide a platform to study disease progression at the cellular level and identify early biomarkers of liver diseases, potentially enabling earlier diagnosis and intervention.

Drug discovery and development are resource-intensive processes. Human liver models allow pharmaceutical companies to screen potential therapeutics more efficiently, reducing the likelihood of late-stage drug failures. This streamlining of drug development processes is driving demand for liver models in the pharmaceutical industry.

Technological Advancements

The Global Human Liver Model Market is currently undergoing a remarkable transformation, largely fueled by rapid technological advancements. These innovations are revolutionizing the field of liver research, drug development, and personalized medicine.

Technological advancements in 3D bioprinting and tissue engineering have transformed the landscape of human liver models. Researchers can now create highly intricate and physiologically accurate liver tissues that closely resemble the real organ. This innovation has significantly enhanced the relevance and reliability of human liver models in drug testing and disease research.

Organ-on-a-chip technology has emerged as a game-changer in the field of liver modeling. These microfluidic devices replicate the physiological conditions of the liver, enabling real-time monitoring and analysis of liver functions. The precision and scalability of organ-on-a-chip systems have opened up new avenues for liver research and drug testing.

Microfabrication techniques have enabled the development of miniaturized liver models with precise control over cell placement and architecture. These models allow for high-throughput screening of drug candidates and provide valuable insights into liver diseases' mechanisms.

Advances in technology have made it possible to create multi-organ systems that mimic the interactions between the liver and other organs in the body. These systems provide a more holistic understanding of how drugs and diseases affect the entire human body, promoting a more accurate evaluation of drug candidates' safety and efficacy.

Cutting-edge imaging techniques, such as high-resolution microscopy and advanced analytical tools, enable researchers to closely monitor and analyze liver models' behavior. This detailed insight into cellular and molecular processes enhances our understanding of liver function and disease progression.

AI and machine learning algorithms are being integrated into liver modeling to analyze vast datasets generated by advanced technologies. These AI-driven approaches help in predicting drug responses, identifying potential biomarkers, and optimizing experimental conditions, ultimately accelerating research and development.

Technological advancements have contributed to the improved reproducibility and scalability of human liver models. This makes it easier for researchers and pharmaceutical companies to conduct large-scale experiments and increase the efficiency of drug screening processes.

Key Market Challenges

Complexity of Liver Functionality

The liver is an incredibly complex organ with numerous functions, including detoxification, metabolism, and protein synthesis. Replicating all of its functions accurately in a model is challenging. Researchers are working on improving the physiological relevance of liver models, but achieving a complete emulation remains a formidable task.

Long-term Viability

Maintaining the viability and functionality of human liver models over an extended period is a challenge. Cells in these models can deteriorate over time, affecting the reliability of experimental results. Researchers are exploring strategies such as bioprinting and organ-on-a-chip technology to address this issue.

Interactions with Other Organs

While single liver models provide valuable insights, understanding how the liver interacts with other organs is crucial for comprehensive research. Developing multi-organ systems that replicate these interactions accurately is a challenge that researchers are actively addressing.

Key Market Trends

Multi-Organ-on-a-Chip Systems

The development of multi-organ-on-a-chip systems is a groundbreaking trend. These platforms enable the study of interactions between the liver and other organs, providing a more comprehensive understanding of how drugs and diseases affect the entire human body. Such models hold immense promise for advancing drug development and personalized medicine.

Advanced Tissue Engineering and 3D Bioprinting

Tissue engineering and 3D bioprinting technologies are evolving rapidly. These innovations allow for the creation of highly complex and physiologically accurate liver tissues that closely mimic the real organ. The increased sophistication of liver models enhances their relevance and reliability in drug testing.

Microfluidic and Lab-on-a-Chip Devices

Microfluidic and lab-on-a-chip devices are becoming more sophisticated, enabling precise control of experimental conditions. These platforms offer real-time monitoring and analysis of liver functions, providing valuable insights into drug responses and disease mechanisms.

Segmental Insights

Product Insights

Based on the category of Product, 2D Models are poised to maintain their dominance in the Global Human Liver Model Market for several compelling reasons. Firstly, they offer cost-effective and efficient solutions for studying liver-related diseases and drug testing, making them an attractive choice for both research institutions and pharmaceutical companies. Moreover, 2D Models have been widely adopted and validated over the years, establishing a robust foundation for continued use. Their simplicity and ease of use also contribute to their enduring popularity. Furthermore, as advancements in cell culture techniques and assay development continue to enhance the relevance and accuracy of 2D Models, they are likely to remain the go-to choose for liver research. In the coming years, the growing demand for liver-related studies and the practical advantages of 2D Models are expected to cement their dominant position in the market.

Application Insights

Based on Application, Drug discovery is poised to continue dominating the Global Human Liver Model Market for several compelling reasons. First and foremost, the pharmaceutical industry's unceasing quest for innovative and effective therapies drives a constant demand for reliable liver models to assess drug candidates. Human liver models play an irreplaceable role in early-stage drug testing, enabling researchers to evaluate drug metabolism, toxicity, and efficacy accurately. Moreover, the increasing complexity of drug targets and the push towards personalized medicine necessitate more sophisticated liver models, positioning drug discovery as a key driver of innovation in this market. With ongoing advancements in tissue engineering and biotechnology, drug discovery will likely maintain its dominance in the coming years, ensuring that the Global Human Liver Model Market continues to thrive.

Regional Insights

In 2022, it is foreseen that North America and Europe will claim the lion's share of the market, primarily attributable to their growing investments in research and development, advancements in organ models, and the acceptance of innovative therapeutic possibilities in these regions. Additionally, the rising incidence of liver diseases, coupled with the presence of major market players, is expected to propel market expansion during the projected period. Furthermore, the Asia Pacific region is set to increase its market share due to escalating research and development investments in emerging nations within the region. Furthermore, the ongoing development of healthcare infrastructure and a heightened focus by companies on the creation of novel therapeutics are poised to fortify regional growth.

Key Market Players

• Organovo Holdings Inc

• BioIVT LLC

• InSphero AG

• Emulate Inc

• Mimetas BV

• CN Bio

• Cyfuse Biomedical KK

• Hurel Corp

Report Scope:

In this report, the Global Human Liver Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Liver Model Market, By Product:

• 2D Models
• 3D Bio Printing
• Liver Organoids

Human Liver Model Market, By Application:

• Drug Discovery
• Academics & Research

Human Liver Model Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Human Liver Model Market.

Available Customizations:

• Global Human Liver Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Liver Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 5.2.2. By Application (Drug Discovery, Academics & Research)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Human Liver Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 6.2.2. By Application (Drug Discovery, Academics & Research)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Liver Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Human Liver Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Human Liver Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Human Liver Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 7.2.2. By Application (Drug Discovery, Academics & Research)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Liver Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Human Liver Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. France Human Liver Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Human Liver Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Human Liver Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Human Liver Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 8.2.2. By Application (Drug Discovery, Academics & Research)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Liver Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Human Liver Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. India Human Liver Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Human Liver Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Human Liver Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Human Liver Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 9.2.2. By Application (Drug Discovery, Academics & Research)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Liver Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Human Liver Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Human Liver Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Human Liver Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 10.2.2. By Application (Drug Discovery, Academics & Research)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Liver Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Human Liver Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Human Liver Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Human Liver Model Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Organovo Holdings Inc
  • 14.6.2. BioIVT LLC
  • 14.6.3. InSphero AG
  • 14.6.4. Emulate Inc
  • 14.6.5. Mimetas BV
  • 14.6.6. CN Bio
  • 14.6.7. Cyfuse Biomedical KK
  • 14.6.8. Hurel Corp

15. Strategic Recommendations

16. About Us & Disclaimer